title: [A prospective randomized controlled trial of Sapylin combined with chemotherapy for advanced colon cancer following radical operation].
abstract: OBJECTIVE
  To evaluate the effect of Sapylin combined with intraperitoneal and systemic chemotherapy for advanced colon cancer following radical operation on local recurrence, hepatic metastasis, and overall survival rate.
  
  
  METHODS
  From Jan. 2004 to Dec. 2005,132 patients with stage II or III colon carcinoma after radical operation were randomly divided into two groups: Sapylin combined with chemotherapy(Sapylin) group and the control group. Toxic reaction, local recurrence, hepatic metastasis, and overall survival rate between two groups were compared.
  
  
  RESULTS
  Both groups successfully completed the trial. There was no significant difference in toxic reaction between two groups, the recurrence and hepatic metastasis rate in Sapylin group were lower than those in the control group(9/60, 15.0% vs. 22/72, 30.6%; 11/60,18.3% vs. 22/72, 34.7%, respectively), which were statistically significant (P<0.05 respectively). The 3- year survival rate in Sapylin group was higher than that in control group(73.3% vs. 54.2%), which was statistically significant (P<0.05).
  
  
  CONCLUSIONS
  Sapylin combined with intraperitoneal and systemic chemotherapy can effectively decrease local recurrence and hepatic metastasis,and improve the survival in patients with advanced colon cancer following radical operation.
authors.affiliation: Department of General Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. chenyt1381@medmail.com.cn
authors.forename: You-Ting
authors.initials: YT
authors.lastname: Chen
authors.forename: Zheng
authors.initials: Z
authors.lastname: Shi
authors.forename: Zhi-Shan
authors.initials: ZS
authors.lastname: Chen
authors.forename: Qing-Liang
authors.initials: QL
authors.lastname: He
authors.forename: Yong-Kun
authors.initials: YK
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011184:Postoperative Period; D011446:Prospective Studies; D013297:Streptococcus pyogenes; D015996:Survival Rate
chemical_list: D001688:Biological Products; C569879:streptococcal preparation 722